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Rating
￿Of importance.
Introduction
Helicobacter pylori is a carcinogen and has been
associated with the development of gastric cancer. The
hypothesis to be tested in this meta-analysis is to
determine whether eradication of this organism is
associated with a long-term reduction in the risk for
development of gastric cancer.
Aims
The study’s purpose is to examine whether eradication of
H. pylori infection can reduce the risk for the development
of gastric cancer.
Methods
The authors examined the results of seven studies that met
inclusion criteria by using relevant clinical trials. Relevant
trials were identified through searching PubMed, Embase,
Google Scholar, and the Cochrane Library. To be eligible to
include subjects in this analysis, the randomized clinical trials
wererequiredtocompare aneradication treatmentgrouptoan
untreated group and to provide an analysis of the number of
gastric cancers occurring during follow-up evaluation.
Results
A total of seven studies were considered adequate to meet the
inclusioncriteria.Oneofthestudieswasexcludedafterfurther
analysis. Overall, 27 of 3388 (1.1%) treated patients in the H.
pylori antibiotic treatment group were identified as having
gastric cancer, compared to 56 of 3307 (1.7%) in those
subjects who did not undergo treatment. The authors
identified the relative risk for gastric cancer as 0.65 (95%
CI, 0.43–0.98).
Discussion
The authors conclude that eradication of H. pylori reduces
gastric cancer risk.
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This section compares the meta-analysis under discussion
with other studies that evaluate the role of treatment of H.
pylori infection in reference to the potential positive effects
on prevention of gastric cancer. These studies collectively
provide the reader with perspective when confronted with a
patient with an active infection.
The current article evaluates the protective effects of
treating H. pylori on the potential risk for the later
development of gastric cancer. This article has worldwide
impact, given the high incidence of this infection in
developing nations, particularly in Asia. This meta-
analysis has accordingly focused on enrolling studies from
areas of the world that have a high incidence of infection.
Although this focus could be viewed as a possible
weakness of the inclusion study design, the inclusion of
studies from areas with high disease incidence make this
study more relevant. This study is supported by a clinical
trial evaluating early H. pylori eradication in reducing the
risk of gastric cancer in patients with peptic ulcer disease
[1]. As a corollary, one study showed that H. pylori
infection is associated with a reduced risk of esophageal
cancer [2].
H. pylori is a bacterium that colonizes the relatively
acidic human stomach. Like Escherichia coli,i ti sa
neutralophile, an organism that requires nearly neutral pH
for optimal growth. H. pylori has evolved acid acclimation
and resistance mechanisms to combat gastric acidity,
which permits the colonization of the acidic gastric
mucosa. A major adaptation of the organism to the acidic
gastric environment is the constitutive production of large
amounts of intrabacterial urease [3]. Activation of urease
at acidic pH is a result of the opening of the proton-gated
urea channel, UreI. Opening this channel allows rapid
e n t r yo fu r e ai n t ot h ec y t o p l asm of the organism, where it
is hydrolyzed by urease and the production of NH3 and
CO2.
H. pylori colonization, if left untreated, results in a
persistent, lifelong infection [4, 5]. In developing nations,
the incidence of infection is greater than 80% in adults,
whereas industrialized countries report an incidence of 20–
50%. Immigration of persons from endemic areas of the
world to the United States results in regional increases in
the incidence of disease. Accordingly, H. pylori infection
will remain endemic in the United States for at least
another century [6]. It is estimated that 15–20% of
patients with H. pylori infection develop peptic ulcers
and 3% of infected patients develop gastric cancer [7]. The
two primary forms of gastric cancer that have been
associated with H. pylori infection include adenocarcinoma
and, less commonly, mucosa-associated lymphoid tumors
(MALToma) or lymphomas [4]. Eradication of H. pylori in
patients with duodenal or gastric ulcer cures the disease,
prevents relapse, and reduces the risk of cancer [6–8].
The diagnosis of H. pylori infection can be established
by several methods: endoscopy with biopsy, serum
antibody testing, urea breath testing, and, more recently,
stool antigen assay. During endoscopy, the biopsy results
may be confirmed by one of three methods: biopsy, urease
test, and histology. Although gastric biopsy is usually
considered the gold standard, more studies now rely on
less invasive testing. Accordingly, noninvasive testing is
the preferred method for establishing a diagnosis and
confirming eradication. The sensitivity of urea breath
testing is about 88–95%, and specificity is about 95–
100% [9]. Another method of establishing the diagnosis
is laboratory-based serologic testing using enzyme-linked
immunosorbent assay technology to detect IgG anti-
bodies. Although this test has a uniform high sensitivity
(90%–100%), the variable specificity (76%–96%) and
low accuracy (83%–98%) would exclude this methodol-
ogy for confirming eradication. The presence of H. pylori
in the stool of infected patients has led to the development
of a stool antigen test, which is now a commercially
available enzyme immunoassay (Premier Platinum HpSA
Immunoassay; Meridian Diagnostics, Cincinnati, OH),
thus enabling this method as an accurate modality for
establishing eradication [10]. The accuracy of the test was
evaluated in a study involving 270 patients in whom the
diagnosis of H. pylori was established by endoscopy and
urea breath testing; test sensitivity was 94% and specific-
ity was 86%. Thus, it has been well established that the
stool antigen assay appears to be useful for documenting
whether eradication was successful. Furthermore, the stool
antigen assay is a noninvasive test that, unlike endoscopic
tests, does not place patients at risk of developing
complications. A 2007 guideline from the American
College of Gastroenterology recommends that biopsy for
histopathology is only appropriate if urea breath testing or
stool antigen testing is not feasible or during follow-up of
complicated ulcer disease, and that serologic testing is not
useful for follow-up because many patients continue to
have antibodies for months or years after eradication
therapy [11]. In the meta-analysis under review, four of the
clinical studies relied on ureab r e a t ht e s t i n ga n dt w oo ft h e
studies relied on the rapid urease test. Histology was used
for confirmation in three of the studies.
H. pylori bacterial infection is prevalent in certain US
populations, and leads to the development of peptic ulcer
disease and a predisposition to gastric cancer [2]. Eradica-
tion of H. pylori prevents peptic ulcer disease and reduces
the risk of gastric cancer, and thus is an important
therapeutic strategy for most clinicians [1, 6–8]. Current
H. pylori eradication therapy requires a combination
treatment approach using a proton pump inhibitor (PPI)
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“triple therapy.” Standard eradication therapy requires
treatment for 10–14 days and has a success rate of less
than 75% [12]. The efficacy of various triple-therapy
regimens is undermined by the development of antimicro-
bial resistance by H. pylori [13] and may well contribute
to development of antibiotic resistance of other important
bacterial pathogens [14]. In H. pylori infection, primary
resistance to amoxicillin has not been described. However,
the frequency of clarithromycin resistance is 17–45.4% in
the United States and even higher in Japan. It is estimated
t h a tt h er e s i s t a n c er a t ew o r l d wide is increasing. Metroni-
dazole resistance ranges between 25% and 48% in both
m e na n dw o m e ni nd e v e l o p i n gc o u n t r i e s ,b e c a u s eo ft h e
frequent use of nitro-imidazoles to treat other diseases
[15]. In a recent meta-analysis, primary resistance to
clarithromycin decreased the eradication rate by 50%,
whereas primary resistance to metronidazole decreased the
rate of eradication by 37% [16] .T h er a t eo fe r a d i c a t i o n
using the triple-therapy approach has fallen below 80%
in many regions, as noted in the Maastricht III consensus
report, and the results differ by regions of the world [17].
The development of antimicrobial resistance by H. pylori
is a major factor in unsuccessful eradication, and clari-
t h r o m y c i nt r e a t m e n tm a yc o n t r i b u t et od e v e l o p m e n to f
antibiotic resistance of other important pathogens [13, 14,
18, 19]. Antibiotic therapy is associated with diarrhea and
the potential for the development of pseudomembranous
colitis. Poor patient compliance is also a factor in
unsuccessful eradication. Twice-daily administration of a
PPI and twice-daily administration of two antibiotics for
14 days requires 84 tablets; moreover, compliance with
before-meal administration is necessary because of the
acid secretion–dependent mechanism of the PPI. Addi-
tionally, PPI-based acid control has considerable variabil-
ity because of variability in absorption and drug-drug
interactions owing to metabolism by CYP2C19, which
may account for the lack of universal eradication with
triple therapy. Although the meta-analysis reviewed here
does not specifically address antimicrobial resistance, this
issue is critically important and its omission may result in
this study underestimating the potential relative risk
reduction of the development of gastric cancer. The
importance of eradication is not only for the prevention
and cure of peptic ulcer disease, but also for the prevention
of gastric adenocarcinoma, which is the third leading
cause of cancer deaths in the United States.
Overall, the available data suggest that H. pylorus is a
carcinogen and in certain persons leads to the development
of gastric cancer. Although clinical and epidemiologic
studies show an increase in relative risk for the develop-
ment of gastric cancer in individuals infected with this
organism, the exact mechanism that explains the link
between this organism and carcinogenesis is not known.
Thus, a review of the available literature indicates strong
clinical evidence suggesting that successful eradication of
this organism is related to a reduction in the risk of gastric
cancer. Clearly, a better understanding of this pathophysi-
ological association is needed to better define the pathways
involved in carcinogenesis.
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